Literature DB >> 572101

Angiogenesis capacity as a diagnostic marker for human eye tumors.

D Tapper, R Langer, A R Bellows, J Folkman.   

Abstract

Solid tumors have the capacity to continuously stimulate the proliferation of new capillaries. Aliquots (0.1 cc) of aqueous humor were aspirated from the anterior chamber of the eye of 38 patients undergoing elective ophthalmologic surgery. The material was lyophilized and then inplanted on the chorioallantoic membrane (CAM) of 10-day-old chick embryos for bioassay. The angiogenesis capacity of each sample was graded as negative or positive. Nine of 10 patients with histologically proven retinoblastoma had positive vascular responses. Seven of 11 patients with choroidal malignant melanoma had a positive response to their aqueous humor on the CAM. Aqueous samples from eyes with an iris and ciliary body malignant melanoma and a metastatic breast carcinoma to the iris had a positive angiogenic response. By contrast, only one of 15 patients undergoing operation for cataracts, glaucoma, or other nonmalignant ocular disease showed an angiogenesis response. The one patient who a positive assay later developed lymphocytic leukemia. These studies show that certain intraocular tumors display angiogenesis capacity before clinically evident neovascular changes of floating tumor cells are seen. Patients without tumors showed no angiogenesis response.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 572101

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  13 in total

1.  A pilot study of bevacizumab and interferon-α2b in ocular melanoma.

Authors:  Kristan D Guenterberg; Valerie P Grignol; Kiran V Relekar; Kimberly A Varker; Helen X Chen; Kari L Kendra; Thomas E Olencki; William E Carson
Journal:  Am J Clin Oncol       Date:  2011-02       Impact factor: 2.339

Review 2.  Tumour angiogenesis.

Authors:  F Arnold
Journal:  Ann R Coll Surg Engl       Date:  1985-09       Impact factor: 1.891

3.  Uveal melanomas express vascular endothelial growth factor and basic fibroblast growth factor and support endothelial cell growth.

Authors:  S R Boyd; D S W Tan; L de Souza; M H Neale; N E Myatt; R A Alexander; M Robb; J L Hungerford; I A Cree
Journal:  Br J Ophthalmol       Date:  2002-04       Impact factor: 4.638

4.  Angiogenic activity in the CSF in human malignancies.

Authors:  S López-Pousa; I Ferrier; J M Vich; J Domenech-Mateu
Journal:  Experientia       Date:  1981-04-15

5.  Tumor vascularity and hematogenous metastasis in experimental murine intraocular melanoma.

Authors:  H E Grossniklaus
Journal:  Trans Am Ophthalmol Soc       Date:  1998

6.  Residual intraretinal retinoblastoma after chemoreduction failure.

Authors:  Christopher K Hwang; Thomas M Aaberg; Patricia Chevez-Barrios; Elizabeth Verner-Cole; Dan S Gombos; Evelyn Paysse; Murali Chintagumpala; Weiqing Gao; Hans E Grossniklaus
Journal:  Arch Ophthalmol       Date:  2012-02

7.  Tumour angiogenesis as a prognostic factor for disease dissemination in retinoblastoma.

Authors:  E Ferrari Marback; V E A Arias; A Paranhos; F A Soares; A L Murphree; C M Erwenne
Journal:  Br J Ophthalmol       Date:  2003-10       Impact factor: 4.638

8.  Basic fibroblast growth factor impact on retinoblastoma progression and survival.

Authors:  Colleen M Cebulla; Maria-Elena Jockovich; Yolanda Piña; Hinda Boutrid; Armando Alegret; Amy Kulak; Abigail S Hackam; Sanjoy K Bhattacharya; William J Feuer; Timothy G Murray
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-07-09       Impact factor: 4.799

9.  Detection of biological activity in the cerebrospinal fluid of patients with central nervous system tumors.

Authors:  D Tapper; M A Cahan; H Brem
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

10.  Gelatinase expression in retinoblastoma: modulation of LH(BETA)T(AG) retinal tumor development by anecortave acetate.

Authors:  M Livia Bajenaru; Yolanda Piña; Timothy G Murray; Colleen M Cebulla; William Feuer; Maria-Elena Jockovich; Maria-Encarna Marin Castaño
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-01-27       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.